<?xml version="1.0" ?>
<tei xml:space="preserve">
	<teiHeader>
		<fileDesc xml:id="0"/>
	</teiHeader>
	<text xml:lang="en">
			<front>Chem Biol Drug Des. 2023;102:763-772. <lb/>| 763 <lb/>wileyonlinelibrary.com/journal/cbdd <lb/></front>

			<body>1 | INTRODUCTION <lb/>Chagas disease (CD), which is also referred to as American <lb/>trypanosomiasis (AT) is a potentially fatal condition that <lb/>is caused by Trypanosoma cruzi. This parasite is trans-<lb/>mitted through the bite of an infected insect known as <lb/>a &quot;kissing bug&quot; (Rassi &amp; de Rezende, 2012). Up to seven <lb/>million people worldwide have a T. cruzi infection, and <lb/>about 75 million people living in endemic regions (Latin <lb/>America) are at risk of contracting the disease (Rodriguez <lb/>&amp; Loaiza, 2017). Annually, there are about 12,000 deaths <lb/>attributed to AT. The incidence of AT is rising in both <lb/>endemic and non-endemic regions of the world due to a <lb/>variety of variables, including climate change, and inter-<lb/>national travel (Campos et al., 2017; Velázquez-Ramírez <lb/>et al., 2022). <lb/>Nifurtimox and benznidazole are the only two medi-<lb/>cations currently available for the treatment of CD and <lb/>have been in use since the 1970s. These medications <lb/>have side effects and are only useful in the acute or early <lb/>stages of the infection. Some detrimental effects of these <lb/>drugs include anorexia, nausea, vomiting, seizures, ver-<lb/>tigo, headaches, and dermatitis; consequently causing <lb/>10%-30% of patients to stop taking their medications <lb/>(García-Huertas &amp; Cardona-Castro, 2021). According to <lb/>estimates, AT results in an annual global spending of <lb/>USD 627.5 million, mostly in the form of medical ex-<lb/>penses. The cost per AT patient ranges from $200 in the <lb/>early stages of the disease to $6000 in the chronic stage. <lb/>Due to this cost, AT has been identified as a parasitic <lb/>disease with the highest global burden (Gómez-Ochoa <lb/>et al., 2022). <lb/></body>

			<front>Received: 2 April 2023 | Revised: 7 June 2023 | Accepted: 12 June 2023 <lb/>DOI: 10.1111/cbdd.14284 <lb/>R E S E A R C H A R T I C L E <lb/>2-Aroyl quinazolinone: Synthesis and in vitro anti-parasitic <lb/>activity <lb/>Koketso J. Setshedi 1 | Richard M. Beteck 1 | Omobolanle J. Jesumoroti 1 | <lb/>Kayhan Ilbeigi 2 | Dorien Mabille 2 | Guy Caljon 2 | Frank Van der Kooy 1 | <lb/>Lesetja J. Legoabe 1 <lb/>This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided <lb/>the original work is properly cited. <lb/>© 2023 The Authors. Chemical Biology &amp; Drug Design published by John Wiley &amp; Sons Ltd. <lb/>1 Centre of Excellence for <lb/>Pharmaceutical Sciences, North-West <lb/>University, Potchefstroom, South Africa <lb/>2 Laboratory of Microbiology, <lb/>Parasitology and Hygiene, Infla-Med <lb/>Centre of Excellence, University of <lb/>Antwerp, Antwerp, Belgium <lb/>Correspondence <lb/>Lesetja J. Legoabe, Centre of Excellence <lb/>for Pharmaceutical Sciences, North-<lb/>West University, Private Bag, X6001, <lb/>Potchefstroom, 2520, South Africa. <lb/>Email: lesetja.legoabe@nwu.ac.za <lb/>Funding information <lb/>National Research Foundation <lb/>Abstract <lb/>Trypanosomes and Leishmania are parasitic protozoans that affect millions of <lb/>people globally. Herein we report the synthesis of 2-aroyl quinazolinones and <lb/>their antiprotozoal efficacy against Trypanosoma brucei, Trypanosoma brucei <lb/>rhodesiense, Trypanosoma cruzi, and Leishmania infantum. These compounds <lb/>were counter-screened against a human cell line for cytotoxicity. Thirteen of the <lb/>twenty target compounds in this study inhibited the growth of these parasites, <lb/>with compounds KJ1, and KJ10 exhibiting IC 50 values of 4.7 μM (T. b. brucei) and <lb/>1.1 μM (T. b. rhodesiense), respectively. <lb/>K E Y W O R D S <lb/>2-Aroyl quinazolinone derivatives, anti-leishmanial activity, anti-trypanosomal activity, one-<lb/>pot oxidation <lb/></front>

			<page>764</page> | <lb/>

			<note place="headnote">SETSHEDI et al. <lb/></note>

			<body>Human African trypanosomiasis (HAT), also referred <lb/>to as sleeping sickness, is a neglected disease solely found <lb/>in Africa, and it is caused by Trypanosoma brucei-a par-<lb/>asitic protozoan transmitted to mammals through the bite <lb/>of an infected tsetse fly (Dunn et al., 2021). Two subspecies <lb/>of T. brucei, T. b. gambiense and T. b. rhodesiense, cause <lb/>HAT in humans (Magez et al., 2021). If untreated, the ill-<lb/>ness is almost always lethal (Beteck et al., 2019). <lb/>Sleeping sickness progresses through two distinct <lb/>stages. In the first or early stage of the disease, trypano-<lb/>somes are limited to the blood and lymphatic systems. In <lb/>the second or late stage of the disease, parasites invade the <lb/>central nervous system (Steverding, 2008). <lb/>Depending on whether or not parasites crossed the <lb/>blood-brain barrier (determined by examination of ce-<lb/>rebrospinal fluid obtained by lumbar puncture), the few <lb/>current HAT medications are split into two categories. <lb/>Suramin or pentamidine injections are given intramuscu-<lb/>larly (IM) for Stage 1 HAT. Melarsoprol or eflornithine/ni-<lb/>furtimox combination are used for the treatment of Stage <lb/>2 HAT. Due to the toxicity of the molecules used to treat <lb/>Stage 2 and/or the challenges associated with administer-<lb/>ing them, patients in Stage 2 are typically treated in hospi-<lb/>tals (Eperon et al., 2014; Venturelli et al., 2022). <lb/>Visceral leishmaniasis (VL) is predominantly caused by <lb/>Leishmania donovani and L. infantum parasites-which <lb/>have phlebotomine sand flies as their vector. The risk <lb/>factors for VL include malnutrition, human immunode-<lb/>ficiency virus infection and acquired immunodeficiency <lb/>syndrome (HIV-AIDS), and other immunosuppressive <lb/>diseases/conditions (Adriaensen et al., 2018; Lindoso <lb/>et al., 2016). According to World Health Organization <lb/>(WHO) reports, leishmaniasis poses a threat to 350 mil-<lb/>lion people in 98 countries. In 2020, nearly 90% of all new <lb/>VL cases reported to the WHO came from 10 countries: <lb/>Brazil, China, Ethiopia, Eritrea, India, Kenya, Somalia, <lb/>South Sudan, Sudan, and Yemen (Yimer et al., 2022). East <lb/>Africa is currently the most affected region in the world, <lb/>accounting for 45% of all cases reported to the WHO in <lb/>2018. In the Mediterranean region, Central Asia, and <lb/>South America, VL is extensively dispersed (Carvalho <lb/>et al., 2021; Maroli et al., 2013). Around 700 cases of au-<lb/>tochthonous VL in Southern Europe have been reported <lb/>annually in nine European Union nations (Dujardin <lb/>et al., 2008). Each year, 130 cases on average are reported <lb/>in Morocco (Echchakery et al., 2018) and almost 90% of <lb/>VL cases can result in mortality if appropriate treatment <lb/>is not started promptly (van Griensven &amp; Diro, 2012). Few <lb/>therapeutic options are available, but none of them are <lb/>currently the ideal option because of high toxicity, exorbi-<lb/>tant cost, a lengthy course of therapy, unsuitable mode of <lb/>administration, and patient&apos;s none-compliance which is <lb/>precipitating the emergence of resistance (Freitas-Junior <lb/>et al., 2012). <lb/>Quinazolinone is a heterocyclic molecule having <lb/>two isomers: 2-and 4-quinazolinone (see Figure 1). <lb/>Quinazolinone derivatives have been investigated and <lb/>reported to exhibit a wide spectrum of biological proper-<lb/>ties, including anti-cytotoxin, analgesic, anti-tuberculosis, <lb/>anti-HIV, antibacterial, anti-hypertensive, antifungal, <lb/>anti-inflammatory, anti-diabetic, anti-oxidation, anti-<lb/>malarial, anticonvulsant, anticancer activities (Jafari <lb/>et al., 2016; Liu et al., 2018; Radwan &amp; Alanazi, 2020; <lb/>Rajput &amp; Mishra, 2012; Tiwary et al., 2015). There are <lb/>several synthetic procedures that allow for easy access to <lb/>quinazolinone derivatives. Based on this, we are interested <lb/>in identifying cost-effective anti-parasitic quinazolinone-<lb/>based hits/leads. <lb/>2 | RESULTS AND DISCUSSION <lb/>2.1 | Chemistry <lb/>We synthesized 19 new compounds with various substitu-<lb/>ents at position 2 of the quinazoline scaffold (Scheme 1). <lb/>2.2 | In vitro antiprotozoal activities and <lb/>cell toxicity <lb/>Nineteen compounds were synthesized and tested for <lb/>activity against four parasitic protozoans. Table 1 com-<lb/>piles the IC 50 values of 12 compounds showing activity <lb/>against one or more parasitic protozoans deployed in <lb/>this study. <lb/>Compounds KJ1 and KJ10 had the best antitrypano-<lb/>somal activity in this study, exhibiting low micromolar <lb/>activity of ~5 μM, and ~1 μM against T. b. rhodesiense. The <lb/>activity data suggest that quinazolinones wherein the <lb/>aroyl moiety at position 2 bears Br, or a NO 2 unit promote <lb/>activity against T. b. rhodesiense. KJ10 also demonstrated <lb/>low micromolar activity against T. b. brucei, exhibiting an <lb/>IC 50 value of ~4 μM. Compounds in this study were gener-<lb/>ally not active against T. cruzi, and L. infantum. <lb/> F I G U R E 1 Structures of 2-and 4-quinazolinone. <lb/></body>
				
			<note place="headnote">17470285, 2023, 4, Downloaded from https://onlinelibrary.wiley.com/doi/10.1111/cbdd.14284, Wiley Online Library on [18/06/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License <lb/></note>

			| <page>765 <lb/></page>

			<note place="headnote">SETSHEDI et al. <lb/></note>

			<body>All 19 compounds were also screened against the <lb/>human fetal lung fibroblast (MRC-5) cell line to investi-<lb/>gate potential toxicity to normal human cells. The min-<lb/>imum concentration required to reduce cell viability by <lb/>50% (CC 50 ) was determined for all compounds. Only KJ25 <lb/>and KJ26 exhibited moderate cell toxicity with CC 50 val-<lb/>ues of 15 μM and 12 μM, respectively. Quinazolinone de-<lb/>rivatives investigated in this study generally showed weak <lb/>to little toxicity against the MRC-5 cell line. <lb/>As most of the molecules investigated were more ac-<lb/>tive against T. b. rhodesiense, activity data against this <lb/>target was used to generate a selectivity index (SI) in re-<lb/>lation to the MRC-5 cell line. SI is the ratio of cytotoxicity <lb/>against MRC-5 cells and activity against T. b. rhodesiense. <lb/>Compounds with SI values &gt;10 are presumed to have <lb/>intrinsic activity against the target, with minimal risk to <lb/>mammalian or human cells. The calculated SI for T. b. rh-<lb/>odesiense ranged from 0.5 to &gt;55. <lb/>3 | MATERIALS AND METHODS <lb/>3.1 | Chemical and instrumentation <lb/>Reagents and solvents were purchased from Merck (Pty) <lb/>Ltd and were used as supplied. Thin layer chromatogra-<lb/>phy (TLC), making use of Merck 60F 254 silica gel plates <lb/>supported on 0.20 mm thick aluminum sheets, was used <lb/>to monitor reactions. After development, plates were <lb/>visualized under ultraviolet (UV) light at 254 nm and <lb/>366 nm and/or in an iodine chamber. Where necessary, <lb/>the crude compounds were purified by silica gel col-<lb/>umn chromatography using Merck Kieselgel 60 Å: 70-<lb/>230 (0.068-0.2 mm) silica gel mesh. 1 H and 13 C NMR <lb/>spectra were recorded on a Bruker Biospin 600 MHz <lb/>spectrometer. Chemical shift data are reported relative <lb/>to the residual solvent peaks (DMSO d 6 : 2.5 ppm for 1 H <lb/>and 39.5 ppm for 13 C). MestReNova software was used <lb/>to process the spectra. The J-coupling constants and <lb/>chemical shifts were measured in Hertz (Hz) and parts <lb/>per million (ppm) respectively. Signal multiplicities are <lb/>denoted as follows: s for a singlet, d for a doublet, dd for <lb/>the doublet of doublet, ddd for the doublet of the dou-<lb/>blet of the doublets, t for a triplet and m for a multiplet. <lb/>High-resolution mass spectra (HRMS) were recorded on <lb/>Bruker micrOTOF-Q II mass spectrometer using atmos-<lb/>pheric pressure chemical ionization (APCI) technique <lb/>in positive ion mode. A Büchi® melting point appara-<lb/>tus (Model B-545, AC/DC input 230 V AC) was used to <lb/>determine the melting points of the target compounds. <lb/>A Bruker ALPHA FTIR spectrometer with a Diamond <lb/>Crystal ATR (Attenuated Total Internal Reflectance) <lb/>accessory was used for the Fourier-transform infrared <lb/>spectroscopy (FTIR). <lb/>3.2 | Procedures for the synthesis of <lb/>target compounds <lb/>A mixture of acetophenone (441.2 mg, 3.67 mmol), I 2 <lb/>(1.1 equiv), 2-aminobenzamide (1.0 equiv), and DMSO <lb/>(15 mL) was stirred at 110°C for 18-48 h. After reaction <lb/>S C H E M E 1 Synthetic route for the preparation of 2-aroyl-quinazolin-4(3H)-ones. A variety of spectroscopic techniques, including FTIR, <lb/>1 <lb/>H NMR, 13 C NMR, and high-resolution mass spectrometry, were used to characterize the target compounds. The signal at 12 ppm in the <lb/>1 <lb/>H NMR spectra is assignable to the amide -NH-unit, which confirms the formation of the quinazolinone core. In the 13 C NMR, the amide <lb/>carbonyl carbon appears at ca 152 ppm, while the peak at ca 188 ppm is assignable to the carbonyl carbon at position 2 of the quinazolinone <lb/>core. The molecular ion peak was confirmed for all compounds using APCI/HRMS. The FTIR spectra of all target compounds displayed <lb/>absorbances at 3000 cm -1 (N-H-stretching), 1640 and 1730 cm -1 (C=O-stretching). <lb/>N <lb/>NH <lb/>O <lb/>O <lb/>NH 2 <lb/>NH 2 <lb/>O <lb/>O <lb/>R 1 <lb/>+ <lb/>I 2 , DMSO, 110 O C <lb/>1 <lb/>2 <lb/>KJ1-KJ35 <lb/>R 1 <lb/>1 <lb/>3 <lb/>4 <lb/>5 <lb/>6 <lb/>7 <lb/>8 <lb/>2 <lb/>2a 2b <lb/>2c <lb/>2d <lb/>2e <lb/>2f <lb/>KJ1:R 1 = 2 d -Br <lb/>KJ2: R 1 = 2 c -Cl; 2 f -OH <lb/>KJ7: R 1 = 2 d -benzene <lb/>KJ8: R 1 = 2 c -MeO; 2 d -OH <lb/>KJ10: R 1 = 2 d -NO 2 <lb/>KJ12: R 1 = 2 c -NO 2 <lb/>KJ14: R 1 = 2 d -OH <lb/>KJ16: R 1 = 2 d -Cl <lb/>KJ17: R 1 = 2 b -benzyloxy <lb/>KJ18: R 1 = 2 d -CH 2 CH 3 <lb/>KJ21: R 1 = 2 c -MeO; 2 d -benzyloxy <lb/>KJ23: R 1 = 2 d -ethoxy; 2 e -MeO <lb/>KJ25: R 1 = 2 b -p-Cl-benzyloxy <lb/>KJ26: R 1 = 2 b -p-Br-benzyloxy <lb/>KJ31: R 1 = 2 c -MeO; 2 d -p-NO 2 -benzyloxy <lb/>KJ32: R 1 = 2 c -MeO; 2 d -p-Br-benzyloxy <lb/>KJ33: R 1 = 2 c -MeO; 2 d -OCH 2 CH 2 CHCH 3 CH 3 <lb/>KJ34: R 1 = 2 b -p-methylbenzyloxy <lb/>KJ35: R 1 = 2 b -p-NO 2 -benzyloxy <lb/></body>

			<note place="headnote">17470285, 2023, 4, Downloaded from https://onlinelibrary.wiley.com/doi/10.1111/cbdd.14284, Wiley Online Library on [18/06/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License <lb/></note>

			<page>766</page> | <lb/>

			<note place="headnote">SETSHEDI et al. <lb/></note>

			<body>completion, 50 mL of water and 50 mL of saturated brine <lb/>solution were added to the mixture and extracted with <lb/>dichloromethane (50 mL ×3). The organic phase was <lb/>washed with a 10% solution of Na 2 S 2 O 3 , dried over an-<lb/>hydrous Na 2 SO 4 and concentrated in vacuo to furnish <lb/>the crude products. Crudes were purified through recrys-<lb/>tallization from ethyl acetate or flushed through a silica <lb/>gel column using DCM as the mobile phase (Fletcher-<lb/>Charles et al., 2022; Kim et al., 2020). <lb/>3.2.1 | Williamson Ether synthesis <lb/>The general procedure of alkylation with alkyl halides <lb/>of 2a-2j <lb/>A round-bottom flask was charged with 2 mL of appro-<lb/>priately substituted acetophenone, aryl/alkyl halide (1.0 <lb/>equiv), and K 2 CO 3 (1.2 equiv). Acetonitrile (15 mL) was <lb/>added, and the mixture was stirred under reflux for 16 h. <lb/>Once the reaction was completed, 50 mL of water was <lb/>T A B L E 1 Results of anti-parasitic activity, cytotoxicity, and selectivity index of selected 2-aroylquinazolin-4(3H)-ones derivatives. <lb/>Compound <lb/>N <lb/>NH <lb/>O <lb/>O <lb/>R 1 <lb/>1 <lb/>3 <lb/>4 <lb/>5 <lb/>6 <lb/>7 <lb/>8 <lb/>2 <lb/>2a 2b <lb/>2c <lb/>2d <lb/>2e <lb/>2f <lb/>Anti-parasitic activity IC 50 (μM) <lb/>Cytotoxicity <lb/>IC 50 (μM) <lb/>Selectivity <lb/>index (SI) <lb/>Entry <lb/>R 1 -position <lb/>T.b. Cruz <lb/>L. Inf <lb/>T.b. bruc <lb/>T.b. rhod <lb/>MRC-5 <lb/>MRC-5/T.b. <lb/>rhod <lb/>KJ1 <lb/>2 d -Br <lb/>&gt;64 <lb/>43.07 <lb/>&gt;64 <lb/>4.73 <lb/>&gt;64.00 <lb/>&gt;13.5 <lb/>KJ2 <lb/>2 c -Cl, 2 f -OH <lb/>41.78 <lb/>43.07 <lb/>&gt;64 <lb/>51.18 <lb/>37.20 <lb/>0.7 <lb/>KJ7 <lb/>2 d -<lb/>&gt;64.00 <lb/>&gt;64.00 <lb/>&gt;64.00 <lb/>&gt;64.00 <lb/>&gt;64.00 <lb/>n.d <lb/>KJ10 <lb/>2 d -NO 2 <lb/>&gt;64.00 <lb/>36.16 <lb/>4.46 <lb/>1.16 <lb/>&gt;64.00 <lb/>&gt;55.2 <lb/>KJ12 <lb/>2 c -NO 2 <lb/>&gt;64.00 <lb/>&gt;64.00 <lb/>&gt;64.00 <lb/>17.45 <lb/>&gt;64.00 <lb/>&gt;3.7 <lb/>KJ16 <lb/>2 d -Cl <lb/>32.24 <lb/>&gt;64.00 <lb/>&gt;64.00 <lb/>36.52 <lb/>53.20 <lb/>1.5 <lb/>KJ17 <lb/>2 b -<lb/>O <lb/>&gt;64.00 <lb/>&gt;64.00 <lb/>&gt;64.00 <lb/>&gt;64.00 <lb/>&gt;64.00 <lb/>n.d <lb/>KJ18 <lb/>2 d -<lb/>&gt;64.00 <lb/>24.05 <lb/>&gt;64.00 <lb/>37.91 <lb/>28.32 <lb/>0.7 <lb/>KJ23 <lb/>2 d -ethoxy; 2 e -MeO <lb/>&gt;64.00 <lb/>&gt;64.00 <lb/>26.02 <lb/>25.71 <lb/>55.96 <lb/>2.2 <lb/>KJ25 <lb/>2 b -<lb/>O <lb/>Cl <lb/>31.12 <lb/>32.46 <lb/>28.32 <lb/>22.03 <lb/>15.25 <lb/>0.7 <lb/>KJ26 <lb/>2 b -<lb/>O <lb/>Br <lb/>31.01 <lb/>24.05 <lb/>28.85 <lb/>24.76 <lb/>12.49 <lb/>0.5 <lb/>KJ31 <lb/>2 c -MeO <lb/>2 d -<lb/>O <lb/>NO 2 <lb/>&gt;64.00 <lb/>&gt;64.00 <lb/>&gt;64.00 <lb/>27.18 <lb/>32.68 <lb/>1.2 <lb/>Abbreviations: L. inf, Leishmania infatum; n.d, not detected; SI, selectivity index; T.b. bruc, Trypanosoma brucei brucei; T.b. cruz, Trypanosoma cruzi; T.b. rhod, <lb/>Trypanosoma brucei rhodesiense; μM, micromolar concentrations. <lb/></body>

			<note place="headnote">17470285, 2023, 4, Downloaded from https://onlinelibrary.wiley.com/doi/10.1111/cbdd.14284, Wiley Online Library on [18/06/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License <lb/></note>

			| <page>767 <lb/></page>

			<note place="headnote">SETSHEDI et al. <lb/></note>

			<body>added, and the mixture was stirred for an additional 5 min. <lb/>The ensuing precipitate was filtered, dried, and used in <lb/>the next step without further purification. <lb/>3.3 | 2-(4-bromobenzoyl) <lb/>quinazolin-4(3h)-one (KJ1) <lb/>White powder, yield 3.89%, m.p 240-243°C. 1 H NMR <lb/>(600 MHz, DMSO-d 6 ) δ 12.74 (s, 1H), 8.48 (d, J = 1.9 Hz, <lb/>1H), 8.19-8.09 (m, 3H), 7.83-7.79 (m, 2H), 7.75 (dt, <lb/>J = 10.2, 5.1 Hz, 1H), 7.56 (d, J = 8.5 Hz, 1H), 7.52 (dd, <lb/>J = 8.1, 3.3 Hz, 1H). 13 C NMR (151 MHz, DMSO-d 6 ) δ <lb/>185.9, 148.9, 143.0, 142.8, 134.3, 134.1, 133.0, 132.4, 131.5, <lb/>129.7, 129.7, 128.5, 124.5. IR (ATR) V max cm -1 : 665.31 <lb/>(C-Br stretching), 1602.40 (C=N stretching), 1660.00 <lb/>(C=O stretching), and 2917.62 (N-H stretching). The <lb/>HRMS (APCI) m/z [M + H] + calculated for C 15 H 10 BrN 2 O 2 <lb/>328.9920; found: 328.9900. <lb/>3.4 | 2-(5-chloro-2-hydroxybenzoyl) <lb/>quinazolin-4(3h)-one (KJ2) <lb/>Mustard powder, yield 17.30% and m.p 300.4-302.2°C. 1 H <lb/>NMR (600 MHz, DMSO-d 6 ) δ 13.80 (s, 1H), 12.51 (s, 1H), <lb/>8.33 (d, J = 2.6 Hz, 1H), 8.15 (dd, J = 7.9, 1.2 Hz, 1H), 7.86-<lb/>7.86 (m, 1H), 7.77 (d, J = 7.9 Hz, 1H), 7.56 (d, J = 8.3 Hz, <lb/>1H), 7.47 (dd, J = 8.8, 2.5 Hz, 1H), 7.02 (dd, J = 8.8, 4.8 Hz, <lb/>1H). 13 C NMR (151 MHz, DMSO-d 6 ) δ 192.0, 158.6, 152.6, <lb/>143.2, 135.0, 134.2, 133.3, 133.1, 127.3, 127.2, 127.1, 126.0, <lb/>122.6, 122.5, 119.6. IR (ATR) V max cm -1 : 580.24 (C-Cl <lb/>stretching), 1608.59 (C=O stretching), 1673.23 (C=N <lb/>stretching), 2987.78 (N-H stretching), and 3151.01 (O-H <lb/>stretching). The HRMS (APCI) m/z [M + H] + calculated <lb/>for C 15 H 10 ClN 2 O 3 301.0374; found: 301.0375. <lb/>3.5 | 2-([1,1′-biphenyl]-4-carbonyl) <lb/>quinazolin-4(3h)-one (KJ7) <lb/>White powder, yield 16.28% and m.p 199°C. 1 H NMR <lb/>(600 MHz, DMSO-d 6 ) δ 12.59 (s, 1H), 8.27 (d, J = 8.4 Hz, <lb/>2H), 8.23 (dd, J = 7.9, 0.9 Hz, 1H), 7.89 (d, J = 8.4 Hz, <lb/>3H), 7.80 (t, J = 7.4 Hz, 3H), 7.66 (t, J = 7.6 Hz, 1H), <lb/>7.52 (t, J = 7.6 Hz, 2H), 7.45 (t, J = 7.3 Hz, 1H). 13 C NMR <lb/>(151 MHz, DMSO-d 6 ) δ 186.5, 161.1, 149.1, 147.1, 145.5, <lb/>138.7, 134.7, 132.9, 131.6, 129.1, 128.6, 128.5, 128.3, <lb/>127.1, 126.7, 126.0, 122.8. IR (ATR) V max cm -1 : 1665.69 <lb/>(C=O stretching), 1694.90 (C=N stretching), 2914.43 <lb/>(C-H stretching), and 2960.08 (N-H stretching). The <lb/>HRMS (APCI) m/z [M + H] + calculated for C 21 H 15 N 2 O 2 <lb/>327.1128; found: 327.1138. <lb/>3.6 | 2-(4-hydroxy-3-methoxybenzoyl) <lb/>quinazolin-4(3h)-one (KJ8) <lb/>Yellow powder, yield 14.71% and m.p 209°C. 1 H NMR <lb/>(600 MHz, DMSO-d 6 ) δ 12.42 (s, 1H), 10.27 (s, 1H), 8.23 (d, <lb/>J = 1.8 Hz, 1H), 8.12 (d, J = 7.4 Hz, 1H), 7.84 (d, J = 1.6 Hz, <lb/>1H), 7.82 (d, J = 7.1 Hz, 1H), 7.79 (d, J = 9.7 Hz, 1H), 7.73 <lb/>(d, J = 8.1 Hz, 1H), 7.48 (t, J = 7.4 Hz, 1H), 3.94 (s, 3H). <lb/>13 <lb/>C NMR (151 MHz, DMSO-d 6 ) δ 180.6, 162.2, 150.6, <lb/>149.2, 148.7, 146.6, 134.5, 130.1, 127.3, 126.2, 125.8, 125.0, <lb/>120.6, 110.9, 84.4, 56.3. IR (ATR) V max cm -1 : 1641.96 (C-H <lb/>stretching), 1675.81 (C=O stretching), 1689.02 (C=N <lb/>stretching), 2970.13 (N-H stretching), and 3178.00 (O-H <lb/>stretching). The HRMS (APCI) m/z [M + H] + calculated <lb/>for C 16 H 13 N 2 O 4 297.0870; found: 297.0851. <lb/>3.7 | 2-(4-nitrobenzoyl) <lb/>quinazolin-4(3h)-one (KJ10) <lb/>Yellow powder, yield 11.07% and m.p 225°C. 1 H NMR <lb/>(600 MHz, DMSO-d 6 ) δ 12.54 (s, 1H), 8.42 (d, J = 8.9 Hz, <lb/>2H), 8.38 (d, J = 8.8 Hz, 2H), 8.24 (d, J = 7.0 Hz, 1H), <lb/>7.90 (t, J = 7.6 Hz, 1H), 7.79 (d, J = 8.0 Hz, 1H), 7.68 (t, <lb/>J = 7.5 Hz, 1H). 13 C NMR (151 MHz, DMSO-d 6 ) δ 185.6, <lb/>160.6, 150.0, 147.8, 146.6, 139.2, 134.4, 131.9, 128.7, <lb/>128.2, 125.8, 122.9, 122.8. IR (ATR) V max cm -1 : 1546.56 <lb/>(N-O stretching), 1662.73 (C=N stretching), 1701.00 <lb/>(C=O stretching), and 2916.02 (N-H stretching). The <lb/>HRMS (APCI) m/z [M + H] + calculated for C 15 H 10 N 3 O 4 <lb/>296.0666; found: 296.0672. <lb/>3.8 | 2-(3-nitrobenzoyl) <lb/>quinazolin-4(3h)-one (KJ12) <lb/>Olive green powder, yield 10.88% and m.p 244°C. 1 H NMR <lb/>(600 MHz, DMSO-d 6 ) δ 12.92 (s, 1H), 9.01 (t, J = 2.0 Hz, <lb/>1H), 8.61-8.59 (m, 1H), 8.43-8.40 (m, 1H), 8.17-8.10 (m, <lb/>1H), 7.89-7.76 (m, 3H), 7.56 (dt, J = 3.2, 2.2 Hz, 1H). 13 C <lb/>NMR (151 MHz, DMSO-d 6 ) δ 160.8, 147.9, 143.0, 134.7, <lb/>134.2, 134.0, 133.9, 130.2, 127.1, 125.9, 125.7, 122.7, 122.6, <lb/>121.2, 92.2. IR (ATR) V max cm -1 : 1502.97 (N-O stretch-<lb/>ing), 1668.69 (C=O stretching), and 2965.20 (N-H stretch-<lb/>ing). The HRMS (APCI) m/z [M + H] + calculated for <lb/>C 15 H 10 N 3 O 4 296.0666; found: 296.0671. <lb/>3.9 | 2-(4-hydroxybenzoyl) <lb/>quinazolin-4(3h)-one (KJ14) <lb/>Mustard powder, yield 23.63% and m.p 227.3-229.6°C. <lb/>1 H NMR (600 MHz, DMSO-d 6 ) δ 12.56 (s, 1H), 11.66 (s, <lb/></body>
				
			<note place="headnote">17470285, 2023, 4, Downloaded from https://onlinelibrary.wiley.com/doi/10.1111/cbdd.14284, Wiley Online Library on [18/06/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License <lb/></note>

			<page>768</page> | <lb/>

			<note place="headnote">SETSHEDI et al. <lb/></note>

			<body>1H), 8.60-8.56 (m, 2H), 8.21 (dd, J = 8.1, 1.1 Hz, 1H), <lb/>8.12-8.09 (m, 1H), 7.91-7.88 (m, 1H), 7.78 (dd, J = 7.7, <lb/>4.4 Hz, 1H), 7.65 (ddd, J = 6.8, 6.2, 2.8 Hz, 1H), 7.03 (d, <lb/>J = 8.6 Hz, 1H). 13 C NMR (151 MHz, DMSO-d 6 ) δ 183.8, <lb/>162.3, 142.2, 138.4, 134.7, 134.7, 133.3, 128.5, 127.0, <lb/>126.0, 126.0, 114.5, 85.8. IR (ATR) V max cm -1 : 1643.29 <lb/>(C=N stretching), 1672.41 (C=O stretching), 2987.46 <lb/>(N-H stretching), and 3291.67 (O-H stretching). The <lb/>HRMS (APCI) m/z [M + H] + calculated for C 15 H 11 N 2 O 3 <lb/>267.0745; found: 267.0745. <lb/>3.10 | 2-(4-chlorobenzoyl) <lb/>quinazolin-4(3h)-one (KJ16) <lb/>White powder, yield 11.67% and m.p 231°C. 1 H NMR <lb/>(600 MHz, DMSO-d 6 ) δ 12.78 (s, 1H), 8.40 (d, J = 2.1 Hz, <lb/>1H), 8.21-8.08 (m, 3H), 7.86-7.70 (m, 1H), 7.67-7.64 <lb/>(m, 1H), 7.63-7.59 (m, 1H), 7.57-7.50 (m, 1H). 13 C NMR <lb/>(151 MHz, DMSO-d 6 ) δ 185.7, 142.9, 139.2, 134.6, 134.3, <lb/>134.1, 132.7, 129.6, 129.5, 128.6, 128.6, 126.7, 125.8. IR <lb/>(ATR) V max cm -1 : 586.61 (C-Cl stretching), 1665.04 <lb/>(C=O stretching), and 2925.77 (N-H stretching). The <lb/>HRMS (APCI) m/z [M + H] + calculated for C 15 H 10 ClN 2 O 2 <lb/>285.0425; found: 285.0400. <lb/>3.11 | 2-(2-(benzyloxy)benzoyl) <lb/>quinazolin-4(3h)-one (KJ17) <lb/>White powder, yield 24.45%, and m.p 168°C. 1 H NMR <lb/>(600 MHz, DMSO-d 6 ) δ 12.65 (s, 1H), 8.11 (dd, J = 7.9, <lb/>1.2 Hz, 1H), 7.84-7.81 (m, 1H), 7.73-7.63 (m, 2H), 7.60-<lb/>7.56 (m, 1H), 7.53-7.48 (m, 1H), 7.42-7.39 (m, 1H), 7.30-<lb/>7.25 (m, 1H), 7.17 (s, 1H), 7.11 (t, J = 7.3 Hz, 1H), 6.99-6.95 <lb/>(m, 2H), 6.93 (d, J = 7.1 Hz, 1H), 5.15-4.93 (m, 2H). 13 C <lb/>NMR (151 MHz, DMSO-d 6 ) δ 189.1, 160.9, 158.1, 150.9, <lb/>147.5, 135.5, 135.0, 134.5, 130.5, 128.5, 127.9, 127.8, 127.7, <lb/>127.6, 127.2, 127.0, 126.0, 125.3, 122.7, 121.0, 113.5, 70.0. <lb/>IR (ATR) V max cm -1 : 1608.62 (C-N stretching), 1660.65 <lb/>(C=O stretching), and 2971.62 (N-H stretching). The <lb/>HRMS (APCI) m/z [M + H] + calculated for C 22 H 17 N 2 O 3 <lb/>357.1234; found: 357.1250. <lb/>3.12 | 2-(4-ethylbenzoyl) <lb/>quinazolin-4(3h)-one (KJ18) <lb/>Yellow powder, yield 12.52% and m.p 168°C. 1 H NMR <lb/>(600 MHz, DMSO-d 6 ) δ 12.81 (s, 1H), 8.47 (d, J = 2.0 Hz, <lb/>1H), 8.17 (dd, J = 8.5, 2.0 Hz, 1H), 8.11-8.06 (m, 2H), 7.55 <lb/>(d, J = 8.5 Hz, 1H), 7.43 (d, J = 8.2 Hz, 2H), 2.83-2.61 (m, <lb/>2H), 1.29-1.10 (m, 3H). 13 C NMR (151 MHz, DMSO-d 6 ) <lb/>δ 186.5, 159.8, 151.1, 149.7, 146.4, 143.0, 134.3, 131.5, <lb/>131.0, 130.2, 128.0, 124.5, 94.0, 28.3, 15.1. IR (ATR) V max <lb/>cm -1 : 1648.57 (C=N stretching), 1673.88 (C=O stretch-<lb/>ing), 2871.95 (C-H stretching), and 2961.73 (N-H stretch-<lb/>ing). The HRMS (APCI) m/z [M + H] + calculated for <lb/>C 17 H 15 N 2 O 2 , 279.1128; found: 279.1116. <lb/>3.13 | 2-(4-(benzyloxy)-3-methoxybenzoyl) <lb/>quinazolin-4(3h)-one (KJ21) <lb/>Yellow powder, yield 66.95%, and m.p 102°C. 1 H NMR <lb/>(600 MHz, DMSO-d 6 ) δ 12.79 (s, 1H), 8.47 (d, J = 2.0 Hz, <lb/>1H), 8.24-8.07 (m, 1H), 7.91-7.71 (m, 3H), 7.58-7.52 (m, <lb/>1H), 7.50-7.44 (m, 2H), 7.43-7.38 (m, 2H), 7.37-7.32 (m, <lb/>1H), 7.25-7.19 (m, 1H), 5.36-5.12 (m, 2H), 3.99-3.76 (m, <lb/>3H). 13 C NMR (151 MHz, DMSO-d 6 ) δ 185.0, 159.8, 153.3, <lb/>150.0, 148.8, 146.5, 143.0, 136.2, 134.2, 130.2, 128.5, <lb/>128.4, 128.1, 127.9, 126.7, 126.7, 126.5, 125.9, 112.5, <lb/>112.4, 112.2, 70.0, 55.6. IR (ATR) V max cm -1 : 1264.80 <lb/>(C-O stretching), 1664.82 (C=O stretching), 2871.01 <lb/>(C=N stretching), and 2915.34 (N-H stretching). The <lb/>HRMS (APCI) m/z [M + H] + calculated for C 23 H 19 N 2 O 4 <lb/>387.1339; found: 387.1368. <lb/>3.14 | 2-(4-ethoxy-3-methoxybenzoyl) <lb/>quinazolin-4(3h)-one (KJ23) <lb/>Yellow powder, yield 15.03% and m.p 221°C. 1 H NMR <lb/>(600 MHz, DMSO-d 6 ) δ 12.79 (s, 1H), 8.47 (d, J = 2.0 Hz, <lb/>1H), 8.17 (dd, J = 8.5, 2.1 Hz, 1H), 7.86-7.68 (m, 3H), <lb/>7.56 (d, J = 8.5 Hz, 1H), 7.14-7.08 (m, 1H), 4.17-4.14 (m, <lb/>2H), 3.88-3.82 (m, 3H), 1.37 (s, 3H). 13 C NMR (151 MHz, <lb/>DMSO-d 6 ) δ 199.8, 161.4, 153.7, 150.9, 148.5, 143.0, <lb/>134.2, 131.2, 126.9, 126.1, 125.3, 124.3, 113.8, 112.1, <lb/>111.5, 64.1, 55.5, 14.4. IR (ATR) V max cm -1 : 1125.56 <lb/>(C-O stretching), 1638.90 (C=N stretching), 1675.81 <lb/>(C=O stretching), and 2973.05 (N-H stretching). The <lb/>HRMS (APCI) m/z [M + H] + calculated for C 18 H 17 N 2 O 4 <lb/>325.1183; found: 325.1178. <lb/>3.15 | 2-(2-((4-chlorobenzyl)oxy)benzoyl) <lb/>quinazolin-4(3h)-one (KJ25) <lb/>Light yellow powder, yield 17.9% and m.p 102°C. 1 H NMR <lb/>(600 MHz, DMSO-d 6 ) δ 12.75 (s, 1H), 8.26 (d, J = 2.0 Hz, <lb/>1H), 8.06 (dd, J = 8.5, 2.1 Hz, 1H), 7.82-7.53 (m, 3H), 7.34 <lb/>(d, J = 8.5 Hz, 1H), 7.28 (t, J = 8.5 Hz, 1H), 7.18 (td, J = 7.5, <lb/>3.0 Hz, 1H), 6.99-6.93 (m, 4H), 5.01-4.95 (m, 2H). 13 C NMR <lb/>(151 MHz, DMSO-d 6 ) δ 188.2, 159.5, 158.4, 151.9, 146.7, <lb/>142.7, 135.7, 134.3, 134.1, 132.5, 130.5, 129.5, 129.1, 129.0, <lb/></body>
				
			<note place="headnote">17470285, 2023, 4, Downloaded from https://onlinelibrary.wiley.com/doi/10.1111/cbdd.14284, Wiley Online Library on [18/06/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License <lb/></note>

			| <page>769 <lb/></page>

			<note place="headnote">SETSHEDI et al. <lb/></note>

			<body>127.9, 127.8, 124.5, 121.2, 113.6, 92.9, 69.5, 56.0. IR (ATR) <lb/>V max cm -1 : 576.58 (C-Cl stretching), 1286.37 (C-O stretch-<lb/>ing), 1631.16 (C=N stretching), 1664.80 (C=O stretching), <lb/>and 2969.35 (N-H stretching). The HRMS (APCI) m/z <lb/>[M + H] + calculated for C 22 H 16 ClN 2 O 3 391.0844; found: <lb/>391.0844. <lb/>3.16 | 2-(2-((4-bromobenzyl)oxy)benzoyl) <lb/>quinazolin-4(3h)-one (KJ26) <lb/>Yellow powder, yield 27.96% and m.p 113.9-115.5°C. <lb/>1 H NMR (600 MHz, DMSO-d 6 ) δ 12.75 (s, 1H), 8.27 (d, <lb/>J = 1.9 Hz, 1H), 8.09-8.04 (m, 1H), 7.83-7.53 (m, 3H), <lb/>7.34 (d, J = 8.5 Hz, 1H), 7.27 (t, J = 8.8 Hz, 1H), 7.18 (td, <lb/>J = 7.5, 3.2 Hz, 1H), 7.11 (dd, J = 8.1, 6.3 Hz, 2H), 6.90 <lb/>(dd, J = 8.0, 6.3 Hz, 2H), 4.95 (s, 2H). 13 C NMR (151 MHz, <lb/>DMSO-d 6 ) δ 188.3, 158.4, 158.1, 142.7, 135.7, 135.3, <lb/>134.6, 134.3, 130.8, 130.8, 129.4, 129.2, 127.6, 125.9, <lb/>125.0, 124.5, 121.2, 121.1, 121.1, 120.9, 113.6, 69.6. IR <lb/>(ATR) V max cm -1 : 551.66 (C-Br stretching), 1285.85 (C-O <lb/>stretching), 1662.97 (C=N stretching), 1729.77 (C=O <lb/>stretching), and 2924.56 (N-H stretching). The HRMS <lb/>(APCI) m/z [M + H] + calculated for C 22 H 16 BrN 2 O 3 <lb/>435.0339; found: 435.0317. <lb/>3.17 | 2-(3-methoxy-4-((4-nitrobenzyl) <lb/>oxy)benzoyl)quinazolin-4(3h)-one (KJ31) <lb/>Yellow powder, yield 33.39%, and m.p 224°C. 1 H NMR <lb/>(600 MHz, DMSO-d 6 ) δ 12.79 (s, 1H), 8.46 (d, J = 2.0 Hz, <lb/>1H), 8.27 (t, J = 8.0 Hz, 2H), 8.16 (dd, J = 8.5, 2.0 Hz, 1H), <lb/>7.86-7.71 (m, 5H), 7.56 (d, J = 8.5 Hz, 1H), 7.20 (dd, J = 8.5, <lb/>4.7 Hz, 1H), 5.45-5.32 (m, 2H), 3.93-3.83 (m, 3H). 13 C NMR <lb/>(151 MHz, DMSO-d 6 ) δ 185.0, 159.8, 152.8, 149.9, 148.8, <lb/>147.1, 146.5, 144.1, 143.0, 134.2, 130.2, 128.3, 128.3, 126.9, <lb/>126.6, 124.4, 123.6, 123.6, 112.6, 112.4, 93.9, 68.7, 56.0. <lb/>IR (ATR) V max cm -1 : 1279.480 (C-O stretching), 1587.90 <lb/>(N-O stretching), 1648.83 (C=N stretching), 1684.06 (C=O <lb/>stretching), and 2911.25 (N-H stretching). The HRMS <lb/>(APCI) m/z [M + H] + calculated for C 23 H 18 N 3 O 6 432.1190; <lb/>found: 432.1172. <lb/>3.18 | 2-(4-((4-bromobenzyl)oxy)-3-<lb/>methoxybenzoyl)quinazolin-4(3h)-one <lb/>(KJ32) <lb/>Yellow powder, yield 40.97%, and m.p 220°C. 1 H NMR <lb/>(600 MHz, DMSO-d 6 ) δ 12.79 (s, 1H), 8.47 (d, J = 2.0 Hz, <lb/>1H), 8.17-8.15 (m, 1H), 7.89-7.72 (m, 2H), 7.63-7.54 <lb/>(m, 3H), 7.44-7.41 (m, 3H), 7.19 (dt, J = 8.7, 3.3 Hz, 1H), <lb/>5.23 (s, 2H), 3.84 (s, 3H). 13 C NMR (151 MHz, DMSO-d 6 ) δ <lb/>185.0, 173.0, 159.8, 153.1, 149.9, 148.7, 146.5, 143.0, 135.7, <lb/>134.7, 134.2, 131.4, 131.3, 130.2, 129.9, 126.7, 124.4, 121.2, <lb/>112.5, 112.2, 93.8, 69.1, 55.7. IR (ATR) V max cm -1 : 522.26 <lb/>(C-Br stretching), 1271.97 (C-O stretching), 1656.78 (C=N <lb/>stretching), 1670.95 (C=O stretching), and 2937.61 (N-H <lb/>stretching). The HRMS (APCI) m/z [M + H] + calculated <lb/>for C 23 H 18 BrN 2 O 4 465.0444; found: 465.0455. <lb/>3.19 | 2-(4-(isopentyloxy)-3-<lb/>methoxybenzoyl)quinazolin-4(3h)-ONE <lb/>(KJ33) <lb/>Light yellow powder, yield 26.53% and m.p 182°C. 1 H <lb/>NMR (600 MHz, DMSO-d 6 ) δ 12.41 (s, 1H), 8.38 (s, 1H), <lb/>8.15-8.09 (m, 1H), 7.84-7.79 (m, 3H), 7.49 (d, J = 8.5 Hz, <lb/>1H), 7.12 (d, J = 8.2 Hz, 1H), 4.18-3.71 (m, 5H), 1.65 (d, <lb/>J = 5.8 Hz, 3H), 0.94 (d, J = 5.1 Hz, 6H). 13 C NMR (151 MHz, <lb/>DMSO-d 6 ) δ 183.3, 162.2, 151.0, 148.6, 146.8, 134.6, 134.5, <lb/>134.1, 127.2, 126.0, 125.7, 124.5, 121.2, 121.1, 112.3, 110.8, <lb/>66.7, 55.7, 37.3, 24.5, 22.4. IR (ATR) V max cm -1 : 1136.51 <lb/>(C-O stretching), 1460.59 (C-H bending), 1640.01 (C=N <lb/>stretching), 1655.36 (C=O stretching), and 2996.35 (N-H <lb/>stretching). The HRMS (APCI) m/z [M + H] + calculated <lb/>for C 21 H 23 N 2 O 4 367.1652; found: 367.1657. <lb/>3.20 | 2-(2-((4-methylbenzyl)oxy) <lb/>benzoyl)quinazolin-4(3h)-one (KJ34) <lb/>Light yellow powder, yield 19.33% and m.p 208.4-209.9°C. <lb/>1 H NMR (600 MHz, DMSO-d 6 ) δ 12.72 (s, 1H), 8.24 (d, <lb/>J = 2.0 Hz, 1H), 8.06 (dd, J = 8.5, 2.1 Hz, 1H), 7.75 (dd, <lb/>J = 7.7, 1.7 Hz, 1H), 7.71-7.68 (m, 1H), 7.33 (d, J = 8.5 Hz, <lb/>H), 7.29 (d, J = 8.4 Hz, H), 7.17 (t, J = 7.5 Hz, 1H), 6.79 (d, <lb/>J = 7.8 Hz, 2H), 6.72 (d, J = 7.8 Hz, 3H), 4.90 (s, 2H), 2.22 (s, <lb/>3H). 13 C NMR (151 MHz, DMSO-d 6 ) δ 188.3, 158.6, 151.9, <lb/>146.8, 142.6, 136.9, 135.7, 134.2, 132.0, 130.4, 129.5, 128.5, <lb/>128.4, 127.4, 127.2, 124.4, 124.1, 121.0, 113.5, 92.6, 70.3, <lb/>56.0, 20.9. IR (ATR) V max cm -1 : 1286.91 (C-O stretching), <lb/>1667.22 (C=N stretching), 1731.71 (C=O stretching), and <lb/>2932.93 (N-H stretching). The HRMS (APCI) m/z [M + H] + <lb/>calculated for C 23 H 19 N 2 O 3 371.1390; found: 371.1363. <lb/>3.21 | 2-(2-((4-nitrobenzyl)oxy)benzoyl) <lb/>quinazolin-4(3h)-one (KJ35) <lb/>Yellow powder, yield 81.41% and m.p 228°C. 1 H NMR <lb/>(600 MHz, DMSO-d 6 ) δ 12.79 (s, 1H), 8.14 (d, J = 2.0 Hz, <lb/>1H), 7.94 (dd, J = 7.9, 1.2 Hz, 1H), 7.82-7.74 (m, 3H), 7.71 <lb/>(td, J = 9.3, 1.8 Hz, 1H), 7.59 (d, J = 7.9 Hz, 1H), 7.50-7.45 (m, <lb/></body>
				
			<note place="headnote">17470285, 2023, 4, Downloaded from https://onlinelibrary.wiley.com/doi/10.1111/cbdd.14284, Wiley Online Library on [18/06/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License <lb/></note>

			<page>770</page> | <lb/>

			<note place="headnote">SETSHEDI et al. <lb/></note>

			<body>1H), 7.36-7.18 (m, 4H), 5.14 (s, 1H). 13 C NMR (151 MHz, <lb/>DMSO-d 6 ) δ 188.5, 158.2, 157.9, 146.6, 142.8, 135.7, 135.4, <lb/>134.4, 134.0, 130.6, 130.6, 129.6, 128.2, 128.1, 125.6, 123.0, <lb/>122.9, 121.5, 121.4, 113.7, 92.9, 69.2. IR (ATR) V max cm -1 : <lb/>1274.58 (C-O stretching), 1515.26 (N-O stretching), 1682.42 <lb/>(C=N stretching), 1701.11 (C=O stretching), and 2913.01 <lb/>(N-H stretching). The HRMS (APCI) m/z [M + H] + calcu-<lb/>lated for C 22 H 16 N 3 O 5 402.1082; found: 402.1082. <lb/>3.22 | In vitro anti-parasitic assay <lb/>Anti-parasitic assays were performed as described else-<lb/>where (Bouton et al., 2021; Hulpia et al., 2019). Briefly, to <lb/>evaluate anti-Leishmania activity, L. infantum [MHOM/ <lb/>MA (BE)/67] was used with primary peritoneal mouse <lb/>macrophages as host cells. 3 × 10 4 macrophages were <lb/>infected with 4.5 × 10 5 parasites per well. Compound di-<lb/>lutions were added after 2 h of infection. After 5 days of in-<lb/>cubation, parasite burdens (mean number of amastigotes/ <lb/>macrophage) were assessed microscopically after staining <lb/>with a 10% Giemsa solution. For T. cruzi, the Tulahuen <lb/>CL2, β-galactosidase strain (nifurtimox-sensitive) was <lb/>used and maintained on MRC-5SV2 (human lung fibro-<lb/>blast) 4 × 10 3 cells were infected with 4 × 10 4 parasites per <lb/>well. Parasite burdens were assessed after adding the sub-<lb/>strate CPRG (chlorophenol red β-d-galactopyranoside). <lb/>The change in color was measured spectrophotometrically <lb/>at 540 nm after 4 h incubation at 37°C. Drug susceptibility <lb/>tests for T. brucei were performed using a resazurin assay. <lb/>Susceptibility assays were performed with T. brucei Squib <lb/>42749 or T. b. rhodesiense STIB-90050. T. brucei Squib 427 <lb/>was seeded at 1.5 × 10 4 parasites/well and T. b. rhodesiense <lb/>at 4 × 10 3 parasites per well, followed by the addition of <lb/>resazurin after 24 h (T. brucei) or 6 h (T. b. rhodesiense). <lb/>After the addition of resazurin, plates were incubated for <lb/>another 24 h followed by fluorescence detection. <lb/>In all assays, parasite growth was compared to untreated-<lb/>infected controls (100% growth) and noninfected controls <lb/>(0% growth). Results were expressed as % parasite reduc-<lb/>tion at the different drug concentrations and used to calcu-<lb/>late IC 50 values from the dose-response curves. <lb/>3.23 | In vitro cytotoxicity assay <lb/>MRC-5SV2 cell cytotoxicity was evaluated as described <lb/>elsewhere (Bouton et al., 2021). Briefly, 1.5 × 105 cells/ <lb/>mL cells were cultured with compound dilutions at <lb/>37°C and with 5% CO 2 . Cell growth was compared to <lb/>untreated-control wells (100% cell growth) and medium-<lb/>control wells (0% cell growth). After 3 days of incuba-<lb/>tion, cell viability was assessed fluorimetrically after the <lb/>addition of 50 μL resazurin per well. After 4 h at 37°C, <lb/>fluorescence was measured (λ ex 550 nm, λ em 590 nm). The <lb/>results were expressed as a % reduction in cell growth/ <lb/>viability compared to control wells and an IC 50 value was <lb/>determined. <lb/>4 | CONCLUSION <lb/>Nineteen 2-aroylquinazolin-4(3H)-ones derivatives were <lb/>synthesized, characterized, and evaluated in vitro for anti-<lb/>parasitic activities. Two compounds KJ1 and KJ10 are the <lb/>most intriguing anti-parasitic hits, exhibiting low micro-<lb/>molar activity against T. b. rhodesiense, and T. b. brucei. <lb/>These compounds showed no inhibitory effect on human <lb/>cells (MRC-5), with compound KJ10 having a T. b. rho-<lb/>desiense selectivity index of &gt;55. Compounds in this study <lb/>possess a low molecular weight and are easy to synthesize. <lb/>This allows for further analogues, and/or derivatives with <lb/>drug-like properties to be explored in search of more po-<lb/>tent anti-parasitic compounds. <lb/></body>

			<div type="acknowledgement">ACKNOWLEDGMENTS <lb/>The authors wish to thank Natascha Van Pelt and An <lb/>Matheeussen for their excellent technical assistance. <lb/>LMPH is a partner of the Excellence Centre &apos;Infla-Med&apos; <lb/>(www.uantw erpen.be/infla -med) and participates in <lb/>COST Action CA21111. <lb/></div>

			<div type="annex">FUNDING INFORMATION <lb/>The North-West University and the South African <lb/>National Research Foundation (NRF) financed this study. <lb/>CONFLICT OF INTEREST STATEMENT <lb/>The authors disclose no conflicts of interest. The study&apos;s <lb/>design, data collection, analysis, or interpretation; the <lb/>preparation of the paper; and the choice to publish the <lb/>findings were all made independently of the funders. <lb/></div>

			<div type="availability">DATA AVAILABILITY STATEMENT <lb/>The data that supports the findings of this study are avail-<lb/>able in the supplementary material of this article. <lb/></div>

			<front>ORCID <lb/>Lesetja J. Legoabe https://orcid. <lb/>org/0000-0003-2440-4993 <lb/></front>

			<listBibl>REFERENCES <lb/>Adriaensen, W., Dorlo, T. P., Vanham, G., Kestens, L., Kaye, P. M., <lb/>&amp; Van Griensven, J. (2018). Immunomodulatory therapy of <lb/>visceral leishmaniasis in human immunodeficiency virus-<lb/>coinfected patients. Frontiers in Immunology, 8, 1943. https:// <lb/>doi.org/10.3389/fimmu.2017.01943 <lb/></listBibl>

			<note place="headnote">17470285, 2023, 4, Downloaded from https://onlinelibrary.wiley.com/doi/10.1111/cbdd.14284, Wiley Online Library on [18/06/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License <lb/></note>

			| <page>771 <lb/></page>

			<note place="headnote">SETSHEDI et al. <lb/></note>

			<listBibl>Beteck, R. M., Legoabe, L. J., Isaacs, M., Khanye, S. D., Laming, D., &amp; <lb/>Hoppe, H. C. (2019). Anti-trypanosomal and antimalarial prop-<lb/>erties of tetralone derivatives and structurally, related benzo-<lb/>cycloalkanones. Medicina, 55(5), 206. https://doi.org/10.3390/ <lb/>medic ina55 050206 <lb/>Bouton, J., d&apos;Almeida, A. F., Maes, L., Caljon, G., Van Calenbergh, S., <lb/>&amp; Hulpia, F. (2021). Synthesis and evaluation of 3′-fluorinated <lb/>7-deazapurine nucleosides as antikinetoplastid agents. <lb/>European Journal of Medicinal Chemistry, 216(2021), 113290. <lb/>https://doi.org/10.1016/j.ejmech.2021.113290 <lb/>Campos, M. C., Phelan, J., Francisco, A. F., Taylor, M. C., Lewis, <lb/>M. D., Pain, A., &amp; Kelly, J. M. (2017). Genome-wide mu-<lb/>tagenesis and multi-drug resistance in American try-<lb/>panosomes induced by the front-line drug benznidazole. <lb/>Scientific Reports, 7(1), 1-8. https://doi.org/10.1038/s4159 <lb/>8-017-14986 -6 <lb/>Carvalho, A. M., Guimarães, L. H., Costa, R., Saldanha, M. G., Prates, <lb/>I., Carvalho, L. P., &amp; Carvalho, E. M. (2021). Impaired Th1 re-<lb/>sponse is associated with therapeutic failure in patients with <lb/>cutaneous Leishmaniasis caused by Leishmania braziliensis. <lb/>The Journal of Infectious Diseases, 223(3), 527-535. https://doi. <lb/>org/10.1093/infdi s/jiaa374 <lb/>Dujardin, J.-C., Campino, L., Cañavate, C., Dedet, J.-P., Gradoni, L., <lb/>Soteriadou, K., &amp; Boelaert, M. (2008). Spread of vector-borne <lb/>diseases and neglect of Leishmaniasis, Europe. Emerging <lb/>Infectious Diseases, 14(7), 1013-1018. https://doi.org/10.3201/ <lb/>eid14 07.071589 <lb/>Dunn, N., Wang, S., &amp; Adigun, R. (2021). African trypanosomiasis. <lb/>In StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih. <lb/>gov/books/ NBK51 9580/ <lb/>Echchakery, M., Nieto, J., Boussaa, S., El Fajali, N., Ortega, S., Souhail, <lb/>K., &amp; Moreno, J. (2018). Asymptomatic carriers of Leishmania <lb/>infantum in patients infected with human immunodeficiency <lb/>virus (HIV) in Morocco. Parasitology Research, 117, 1237-1244. <lb/>https://doi.org/10.1007/s0043 6-018-5805-y <lb/>Eperon, G., Balasegaram, M., Potet, J., Mowbray, C., Valverde, O., <lb/>&amp; Chappuis, F. (2014). Treatment options for second-stage <lb/>gambiense human African trypanosomiasis. Expert Review <lb/>of Anti-Infective Therapy, 12(11), 1407-1417. https://doi. <lb/>org/10.1586/14787 210.2014.959496 <lb/>Fletcher-Charles, J., Ferreira, R. R., Abraham, M., Romito, D., <lb/>Oppel, M., González, L., &amp; Bonifazi, D. (2022). Oxygen-doped <lb/>pah electrochromes: Difurano, dipyrano, and furano-pyrano <lb/>containing naphthalene-cored molecules. European Journal of <lb/>Organic Chemistry, 2022, e202101166. https://doi.org/10.1002/ <lb/>ejoc.20210 1166 <lb/>Freitas-Junior, L. H., Chatelain, E., Kim, H. A., &amp; Siqueira-Neto, J. <lb/>L. (2012). Visceral leishmaniasis treatment: What do we have, <lb/>what do we need and how to deliver it? International Journal <lb/>for Parasitology: Drugs and Drug Resistance, 2, 11-19. https:// <lb/>doi.org/10.1016/j.ijpddr.2012.01.003 <lb/>García-Huertas, P., &amp; Cardona-Castro, N. (2021). Advances in the <lb/>treatment of Chagas disease: Promising new drugs, plants and <lb/>targets. Biomedicine &amp; Pharmacotherapy, 142, 112020. https:// <lb/>doi.org/10.1016/j.biopha.2021.112020 <lb/>Gómez-Ochoa, S. A., Rojas, L. Z., Echeverría, L. E., Muka, T., &amp; <lb/>Franco Duran, O. H. (2022). Global, regional, and national <lb/>trends of chagas disease from 1990 to 2019: Comprehensive <lb/>analysis of the global burden of disease study. Global Heart, <lb/>17(1), 59. https://doi.org/10.5334/gh.1150 <lb/>Hulpia, F., Mabille, D., Campagnaro, G. D., Schumann, G., Maes, <lb/>L., Roditi, I., &amp; Van Calenbergh, S. (2019). Combining tu-<lb/>bercidin and cordycepin scaffolds results in highly active <lb/>candidates to treat late-stage sleeping sickness. Nature <lb/>Communications, 10(1), 5564. https://doi.org/10.1038/s4146 <lb/>7-019-13522 -6 <lb/>Jafari, E., Khajouei, M. R., Hassanzadeh, F., Hakimelahi, G. H., &amp; <lb/>Khodarahmi, G. A. (2016). Quinazolinone and quinazoline de-<lb/>rivatives: Recent structures with potent antimicrobial and cyto-<lb/>toxic activities. Research in Pharmaceutical Sciences, 11(1), 1-14 <lb/>https://www.ncbi.nlm.nih.gov/pmc/artic les/PMC47 94932/ <lb/>Kim, S., Li, Y., Lin, L., Sayasith, P. R., Tarr, A. T., Wright, E. B., &amp; <lb/>O&apos;Doherty, G. A. (2020). Synthesis and biological evalua-<lb/>tion of 4′-substituted kaempfer-3-ols. The Journal of Organic <lb/>Chemistry, 85(6), 4279-4288. https://doi.org/10.1021/acs. <lb/>joc.9b03461 <lb/>Lindoso, J. A. L., Cunha, M. A., Queiroz, I. T., &amp; Moreira, C. H. V. <lb/>(2016). Leishmaniasis-HIV coinfection: Current challenges. <lb/>HIV/AIDS-Research and Palliative Care, 8, 147-156. https://doi. <lb/>org/10.2147/HIV.S93789 <lb/>Liu, Z., Zeng, L.-Y., Li, C., Yang, F., Qiu, F., Liu, S., &amp; Xi, B. (2018). <lb/>&quot;On-water&quot; synthesis of quinazolinones and dihydroquinazoli-<lb/>nones starting from o-bromobenzonitrile. Molecules, 23(9), <lb/>2325. https://doi.org/10.3390/molec ules2 3092325 <lb/>Magez, S., Pinto Torres, J. E., Oh, S., &amp; Radwanska, M. (2021). <lb/>Salivarian trypanosomes have adopted intricate host-pathogen <lb/>interaction mechanisms that ensure survival in plain sight of <lb/>the adaptive immune system. Pathogens, 10(6), 679. https://doi. <lb/>org/10.3390/patho gens1 0060679 <lb/>Maroli, M., Feliciangeli, M., Bichaud, L., Charrel, R., &amp; Gradoni, L. <lb/>(2013). Phlebotomine sandflies and the spreading of leishma-<lb/>niases and other diseases of public health concern. Medical <lb/>and Veterinary Entomology, 27(2), 123-147. https://doi. <lb/>org/10.1111/j.1365-2915.2012.01034.x <lb/>Radwan, A. A., &amp; Alanazi, F. K. (2020). Biological activity of <lb/>quinazolinones. International Journal of Medicinal Chemistry, <lb/>2014, 1-27. <lb/>Rajput, R., &amp; Mishra, A. P. (2012). A review on biological activity <lb/>of quinazolinones. International Journal of Pharmacy and <lb/>Pharmaceutical Sciences, 4(2), 66-70. <lb/>Rassi, A., &amp; de Rezende, J. M. (2012). American trypanosomiasis <lb/>(Chagas disease). Infectious Disease Clinics, 26(2), 275-291. <lb/>https://doi.org/10.1016/j.idc.2012.03.002 <lb/>Rodriguez, I. G., &amp; Loaiza, J. R. (2017). American trypanosomiasis, <lb/>or Chagas disease, in Panama: A chronological synopsis of eco-<lb/>logical and epidemiological research. Parasites &amp; Vectors, 10(1), <lb/>1-16. https://doi.org/10.1186/s1307 1-017-2380-5 <lb/>Steverding, D. (2008). The history of African trypanosomiasis. Parasites <lb/>&amp; Vectors, 1(1), 1-8. https://doi.org/10.1186/1756-3305-1-3 <lb/>Tiwary, B. K., Pradhan, K., Nanda, A. K., &amp; Chakraborty, R. (2015). <lb/>Implication of quinazoline-4 (3H)-ones in medicinal chemis-<lb/>try: A brief review. Journal of Chemical Biology &amp; Therapeutics, <lb/>1(104), 2572-2406. https://doi.org/10.4172/2572-0406.1000104 <lb/>van Griensven, J., &amp; Diro, E. (2012). Visceral leishmaniasis. Infectious <lb/>Disease Clinics, 26(2), 309-322. https://doi.org/10.1016/j. <lb/>idc.2012.03.005 <lb/>Velázquez-Ramírez, D. D., de Léon, A. A. P., &amp; Ochoa-Díaz-<lb/>López, H. (2022). Review of American trypanosomiasis in <lb/>southern Mexico highlights opportunity for surveillance re-<lb/>search to advance control through the one health approach. <lb/></listBibl>

			<note place="headnote">17470285, 2023, 4, Downloaded from https://onlinelibrary.wiley.com/doi/10.1111/cbdd.14284, Wiley Online Library on [18/06/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License <lb/></note>

			<page>772</page> | <lb/>

			<note place="headnote">SETSHEDI et al. <lb/></note>

			<listBibl>Frontiers in Public Health, 10, 838949. https://doi.org/10.3389/ <lb/>fpubh.2022.838949 <lb/>Venturelli, A., Tagliazucchi, L., Lima, C., Venuti, F., Malpezzi, G., <lb/>Magoulas, G. E., &amp; Costi, M. P. (2022). Current treatments to <lb/>control african trypanosomiasis and one health perspective. <lb/>Microorganisms, 10(7), 1298. https://doi.org/10.3390/micro <lb/>organ isms1 0071298 <lb/>Yimer, M., Nibret, E., &amp; Yismaw, G. (2022). Updates on prevalence <lb/>and trend status of visceral leishmaniasis at two health facilities <lb/>in Amhara regional state, Northwest Ethiopia: A retrospective <lb/>study. Biochemistry Research International, 2022, 1-7. https:// <lb/>doi.org/10.1155/2022/3603892 <lb/></listBibl>

			<front>How to cite this article: Setshedi, K. J., Beteck, <lb/>R. M., Jesumoroti, O. J., Ilbeigi, K., Mabille, D., <lb/>Caljon, G., Van der Kooy, F., &amp; Legoabe, L. J. (2023). <lb/>2-Aroyl quinazolinone: Synthesis and in vitro <lb/>anti-parasitic activity. Chemical Biology &amp; Drug <lb/>Design, 102, 763-772. https://doi.org/10.1111/ <lb/>cbdd.14284 <lb/></front>

			<note place="headnote">17470285, 2023, 4, Downloaded from https://onlinelibrary.wiley.com/doi/10.1111/cbdd.14284, Wiley Online Library on [18/06/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License </note>


	</text>
</tei>
